Cargando…

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

INTRODUCTION: Patients with systemic lupus erythematosus (SLE) with B-lymphocyte stimulator (BLyS) levels ≥ 2 ng/mL are at increased risk of flare. A regression analysis was undertaken to identify routine clinical measures that correlate with BLyS ≥ 2 ng/mL. Efficacy and safety of belimumab 10 mg/kg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roth, D A, Thompson, A, Tang, Y, Hammer, A E, Molta, C T, Gordon, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785993/ https://www.ncbi.nlm.nih.gov/pubmed/26385220 http://dx.doi.org/10.1177/0961203315604909

Ejemplares similares

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
por: Collins, Christopher E, et al.
Publicado: (2006)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019)

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
por: Stohl, William
Publicado: (2010)

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis
por: Wilkinson, Christel, et al.
Publicado: (2020)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Publicado: (2012)

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
por: López, Patricia, et al.
Publicado: (2016)

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
por: Furie, Richard, et al.
Publicado: (2008)

The current status of targeting BAFF/BLyS for autoimmune diseases
por: Ramanujam, Meera, et al.
Publicado: (2004)

Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
por: Scapini, Patrizia, et al.
Publicado: (2003)

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin
por: Parameswaran, Reshmi, et al.
Publicado: (2012)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells
por: Zhu, Jing, et al.
Publicado: (2012)

Human BLyS Facilitates Engraftment of Human PBL Derived B Cells in Immunodeficient Mice
por: Schmidt, Madelyn R., et al.
Publicado: (2008)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
por: Schwarting, A, et al.
Publicado: (2016)

Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells
por: Sindhava, Vishal J., et al.
Publicado: (2013)

B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance
por: Müller, Nike, et al.
Publicado: (2014)

Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
por: Luster, Troy A., et al.
Publicado: (2012)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus
por: Doria, A, et al.
Publicado: (2018)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2014)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation
por: Goenka, Radhika, et al.
Publicado: (2014)

High Expression Levels of BLyS/BAFF by Blood Dendritic Cells and Granulocytes Are Associated with B-cell dysregulation in SIV-Infected Rhesus Macaques
por: Poudrier, Johanne, et al.
Publicado: (2015)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
por: Cai, Shaozhe, et al.
Publicado: (2023)

APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2022)

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
por: Yapa, S Wickramaratne Senarath, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6tutvjdn1202brkf5o2qdd0uau